Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma
暂无分享,去创建一个
A. Shilatifard | A. G. Robertson | S. Miller | D. Fantini | Yanni Yu | J. Meeks | Lu Wang | A. Piunti | J. Podojil | Kimberly A. McLaughlin | J. Qian | Zonghao You | Khyati Meghani | Ming-Ching Chiang | Yi Luo | Nathan Heyen | Z. You | Damiano Fantini | A. G. Robertson | Joseph R. Podojil | K. Meghani
[1] M. Corazzari,et al. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids , 2021, International journal of molecular sciences.
[2] A. Shilatifard,et al. The roles of Polycomb repressive complexes in mammalian development and cancer , 2021, Nature Reviews Molecular Cell Biology.
[3] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[4] M. Glickman,et al. Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling , 2020, Proceedings of the National Academy of Sciences.
[5] Mauro A. A. Castro,et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. , 2020, European urology.
[6] D. Bajorin,et al. Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) , 2020 .
[7] M. Galsky,et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.
[8] P. Crispen,et al. Mechanisms of immune evasion in bladder cancer , 2019, Cancer Immunology, Immunotherapy.
[9] R. Tothill,et al. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer , 2019, Cancer cell.
[10] P. Robson,et al. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma , 2019, bioRxiv.
[11] Jan Baumbach,et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology , 2019, Bioinform..
[12] Yanni Yu,et al. Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors. , 2019, Journal of visualized experiments : JoVE.
[13] Q. Hu,et al. Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer , 2019, Cell Death & Differentiation.
[14] Gary D Bader,et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap , 2019, Nature Protocols.
[15] Douglas B. Johnson,et al. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer , 2018, Clinical Cancer Research.
[16] L. Dyrskjøt,et al. Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology , 2018, Current opinion in urology.
[17] J. Witjes,et al. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. , 2018, European urology.
[18] A. Shilatifard,et al. A Carcinogen-induced Mouse Model Recapitulates the Molecular Alterations of Human Muscle Invasive Bladder Cancer , 2017, Oncogene.
[19] T. Powles,et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.
[20] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.
[21] O. Boyman,et al. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. , 2017, Cell reports.
[22] D. Speiser,et al. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data , 2017, bioRxiv.
[23] A. Butte,et al. xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, Genome Biology.
[24] Swe Swe Myint,et al. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2 , 2017, Science Translational Medicine.
[25] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.
[26] John D Seigne,et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. , 2016, The Journal of urology.
[27] K. Helin,et al. Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer. , 2016, Cold Spring Harbor perspectives in medicine.
[28] Jun S. Liu,et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.
[29] A. Shilatifard,et al. Epigenetic balance of gene expression by Polycomb and COMPASS families , 2016, Science.
[30] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[31] C. Roberts,et al. Targeting EZH2 in cancer , 2016, Nature Medicine.
[32] Y. Dou,et al. PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. , 2016, Cancer research.
[33] Gianluca Bontempi,et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.
[34] Kathleen R. Cho,et al. Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy , 2015, Nature.
[35] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[36] R. Brosch,et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. , 2014, European urology.
[37] P. Beachy,et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma , 2014, Nature Cell Biology.
[38] K. Helin,et al. Polycomb proteins control proliferation and transformation independently of cell cycle checkpoints by regulating DNA replication , 2014, Nature Communications.
[39] Shih-Ming Huang,et al. Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo , 2014, Oncotarget.
[40] J. Sage,et al. Molecular and Cellular Pathobiology In Vivo Disruption of an Rb – E 2 F – Ezh 2 Signaling Loop Causes Bladder Cancer , 2014 .
[41] Mark W. Ball,et al. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. , 2012, Urologic oncology.
[42] M. Albert,et al. Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer , 2012, Science Translational Medicine.
[43] Nathaniel H. Boyd,et al. Early epigenetic events regulate the adaptive immune response gene CIITA , 2011, Epigenetics.
[44] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[45] H. Pasolli,et al. EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. , 2011, Genes & development.
[46] D. Pasini,et al. Epigenetic factors in cancer development: polycomb group proteins. , 2011, Future oncology.
[47] K. Miller,et al. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder , 2008, Journal of Cancer Research and Clinical Oncology.
[48] T. Curiel,et al. Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.
[49] Yi Luo,et al. Urinary Bladder Epithelium Antigen Induces CD8+ T Cell Tolerance, Activation, and Autoimmune Response1 , 2007, The Journal of Immunology.
[50] M. Dziejman,et al. IFN-γ-Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking1 , 2002, The Journal of Immunology.
[51] Susumu Tonegawa,et al. RAG-1-deficient mice have no mature B and T lymphocytes , 1992, Cell.